Pluvicto
Ended Awarded Last action
- Contract number
- 36C24225N0129
- Awardee
-
Advanced Accelerator Applications USA Inc. UEI JNM4NBNHFE66
- Awarding agency
-
Veterans Integrated Service Network 2
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $132,797
Award facts
- Opportunity
-
- 36C24224Q1008 Solicitation number
- Contract value 100% obligated
- $132,796.51 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Millburn, NJ 07041, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$65,858 | |
| Supplemental Agreement for work within scope | -$1,787,891 | |
| Original award | $1,986,545 |
About this award
Advanced Accelerator Applications USA Inc., a Novartis subsidiary headquartered in Millburn, New Jersey, received a $132,796.51 firm fixed-price blanket purchase agreement call from Veterans Integrated Service Networks (VISN) 2 on October 1, 2024, for PLUVICTO (lutetium Lu 177 vipivotide tetraxetan). This award, which concludes September 30, 2025, was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) without small business set-aside designation. PLUVICTO is a targeted radioligand therapy product used in the treatment of prostate cancer and other malignancies within the federal healthcare system. The Department of Veterans Affairs has been the predominant federal customer for the company's specialized radiopharmaceutical products, awarding multiple delivery orders and BPA calls across numerous VISN regions to support nuclear medicine diagnostic and therapeutic capabilities at VA medical centers nationwide.
This delivery order builds upon Advanced Accelerator Applications USA Inc.'s established portfolio of radiopharmaceutical supply contracts with federal agencies, including a substantial $49.1 million single-award BPA with VISN 9 for PLUVICTO extending through December 2029, additional BPAs with VISN 20 ($6 million through December 2026) and other VISN regions, and contracts with the Defense Health Agency and National Institutes of Health. The company serves as prime contractor with no identified subcontractors, providing direct supply of specialized nuclear medicine products. All contract vehicles maintain firm fixed-price terms and enable federal healthcare agencies to issue task orders and delivery orders on an as-needed basis to support cancer treatment and diagnostic imaging procedures across the VA system and other federal medical facilities.
Quick answers
Who was awarded contract 36C24225N0129?
36C24225N0129 was awarded to Advanced Accelerator Applications USA Inc. by Veterans Integrated Service Network 2 (Veterans Health Administration) on October 1, 2024.
How much is contract 36C24225N0129 worth?
The government has obligated $132,797 on 36C24225N0129.
Is contract 36C24225N0129 an order under another contract?
Yes. 36C24225N0129 is a BPA call under 36F79719D0169-36C24224A0031, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24225N0129 competed?
The extent of competition for 36C24225N0129 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award